Navigation Links
Video: Moms Raise 'Red Flag' About the Dangers of Widely Undiagnosed Bleeding Disorder

National Campaign Highlights Signs, Symptoms, Impact on Families of von

Willebrand Disease

NEW YORK, Sept. 23 /PRNewswire/ -- While an estimated 2.8 million Americans are affected by the most common hereditary bleeding disorder, von Willebrand disease (VWD), most don't even know they have it. VWD affects both men and women, but according to the Centers for Disease Control and Prevention (CDC) it takes a woman an average of 16 years to receive a diagnosis. Now a group of mothers with VWD have joined together to focus attention on the need for more communication between mothers and their children about signs, symptoms and potentially severe health consequences of this disease.

To view the Multimedia News Release, go to:

"Growing up I never knew that what I was experiencing -- the bruising and the heavy periods that would last for days -- had a name," said Jeanette Cesta, 45, who wasn't diagnosed until she was in her 20s. "Because of my diagnosis I was able to ensure that my three children were tested early and received the proper treatment for their VWD."

The National Hemophilia Foundation's Project Red Flag campaign, Real Talk About Women's Bleeding Disorders, educates women about VWD by shining light on the signs and symptoms of the disease which can often present in childhood and puberty. Mothers with VWD are sharing their own stories of diagnosis and treatment to encourage more open communication and family awareness that easy bruising, frequent nosebleeds, and prolonged and heavy menstruation can be symptoms of the disease. Earlier diagnosis is crucial for women with VWD as they are at greater risk for such serious complications as miscarriage, life-threatening bleeding following surgery or childbirth, and undergoing unnecessary hysterectomies, even though their condition can be managed medically.

To help address these issues, The National Heart, Lung and Blood Institute (NHLBI, part of the National Institutes of Health (NIH)) and the U.S. Department of Health and Human Services, recently issued the first-ever clinical guidelines for the diagnosis and treatment of VWD, providing health professionals with evidenced-based recommendations on screening, diagnosis, disease management, and directions for future research.

"Von Willebrand disease can be diagnosed from the patient's history and the results of blood tests," said Peter Kouides, M.D, medical and research director of the Mary M. Gooley Hemophilia Treatment Center in Rochester NY. "While there is no cure for VWD, treatment is available and can help prevent complications. But the disorder must be properly diagnosed."

According to currently available statistics from the CDC, von Willebrand disease affects 1 to 2 percent of Americans. VWD frequently manifests in women as a seemingly gynecological problem, such as heavy or prolonged menstruation. This leads the patient and her doctor to believe the problem is gynecologic. It is, in fact, hematologic, or blood related.

Project Red Flag is NHF's national public awareness campaign created to educate women and their doctors about diagnosing and treating bleeding disorders, and it is supported by an educational grant from CSL Behring.

"Von Willebrand disease is a serious health issue for women," said Val Bias, chief executive officer of the National Hemophilia Foundation. "We encourage all women to increase their knowledge of bleeding disorders and to see their doctor immediately if they suspect they have symptoms."

Know the Five Signs of a Bleeding Disorder

-- Easy bruising of the limbs

-- Frequent or prolonged nosebleeds

-- Heavy menstrual periods

-- Prolonged bleeding after injury, childbirth or surgery

-- Prolonged bleeding during dental work

If you have one or more of these symptoms, contact your primary care physician. You may be need to be screened for a bleeding disorder.

For more information on VWD visit the Project Red Flag web site at or call the National Hemophilia Foundation's Information Resource Center at 1-800-42-HANDI (email to Trained staff members are available Monday through Friday, 9 a.m. to 5:00 p.m. EST to answer your requests.

About the National Hemophilia Foundation and Project Red Flag

The National Hemophilia Foundation is dedicated to finding better treatments and cures for bleeding and clotting disorders and to preventing the complications of these disorders through education, advocacy and research.

Established in 1948, the National Hemophilia Foundation is a non profit 501(c)3 organization with chapters throughout the country. Its programs and initiatives are made possible through the generosity of individuals, corporations and foundations as well as through a cooperative agreement with the Centers for Disease Control and Prevention (CDC).

For more information about the National Hemophilia Foundation visit

About CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Products include Humate P(R) Antihemophilic Factor/von Willebrand Factor Complex (Human) Dried, Pasteurized, for the treatment of von Willebrand Disease, and Helixate(R) FS a recombinant factor VIII treatment for hemophilia A. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit

Press Contact:

Laura de Zutter

MCS Public Relations on behalf of the National Hemophilia Foundation


John Indence

National Hemophilia Foundation


SOURCE National Hemophilia Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Video: Fortune 1000 Executives: New President Must Fix Education Gap
2. Video: Keppra XR(TM) Approved in the U.S.
3. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
4. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
5. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
6. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
7. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
8. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
9. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
10. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
11. Yongye Biotechnology International Raises $9.4 Million in Private Placement
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
Breaking Biology Technology:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):